| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261644556P | 2012-05-09 | 2012-05-09 | |
| US201261644623P | 2012-05-09 | 2012-05-09 | |
| US201261648043P | 2012-05-16 | 2012-05-16 | |
| US201261653362P | 2012-05-30 | 2012-05-30 | |
| US201261664611P | 2012-06-26 | 2012-06-26 | |
| US201261668709P | 2012-07-06 | 2012-07-06 | |
| US201261678053P | 2012-07-31 | 2012-07-31 | |
| US201261702207P | 2012-09-17 | 2012-09-17 | |
| US201261724836P | 2012-11-09 | 2012-11-09 | |
| PCT/US2013/031053WO2013169355A1 (en) | 2012-05-09 | 2013-03-13 | Treatment of myelosuppression |
| Publication Number | Publication Date |
|---|---|
| SG11201407340YAtrue SG11201407340YA (en) | 2014-12-30 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201603059YASG10201603059YA (en) | 2012-05-09 | 2013-03-13 | Treatment Of Myelosuppression |
| SG11201407340YASG11201407340YA (en) | 2012-05-09 | 2013-03-13 | Treatment of myelosuppression |
| SG10201914117QASG10201914117QA (en) | 2012-05-09 | 2013-03-13 | Treatment Of Myelosuppression |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201603059YASG10201603059YA (en) | 2012-05-09 | 2013-03-13 | Treatment Of Myelosuppression |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201914117QASG10201914117QA (en) | 2012-05-09 | 2013-03-13 | Treatment Of Myelosuppression |
| Country | Link |
|---|---|
| US (6) | US9271999B2 (en) |
| EP (2) | EP2846809B1 (en) |
| JP (3) | JP6177885B2 (en) |
| KR (2) | KR102452803B1 (en) |
| CN (3) | CN108498532B (en) |
| AU (1) | AU2013260101B2 (en) |
| BR (1) | BR112014028094B1 (en) |
| CA (2) | CA3122808A1 (en) |
| CL (2) | CL2014003017A1 (en) |
| DK (1) | DK2846809T3 (en) |
| EA (1) | EA029382B1 (en) |
| ES (1) | ES2848050T3 (en) |
| HU (1) | HUE053247T2 (en) |
| IL (1) | IL235593B (en) |
| LT (1) | LT2846809T (en) |
| MX (2) | MX370567B (en) |
| PL (1) | PL2846809T3 (en) |
| PT (1) | PT2846809T (en) |
| SG (3) | SG10201603059YA (en) |
| WO (1) | WO2013169355A1 (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108498532B (en) | 2012-05-09 | 2021-07-23 | 坎泰克斯制药股份有限公司 | Treatment of myelosuppression |
| CN105848672A (en)* | 2013-10-22 | 2016-08-10 | 坎泰克斯制药股份有限公司 | Methods of treating and preventing radiation damage |
| WO2015142924A1 (en) | 2014-03-17 | 2015-09-24 | Cantex Pharmaceuticals, Inc. | Multivalent cation formulations of partially desulfated heparins |
| EP3258941A4 (en) | 2015-02-17 | 2018-09-26 | Cantex Pharmaceuticals, Inc. | Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction |
| SG11201707127VA (en) | 2015-03-06 | 2017-09-28 | Beyondspring Pharmaceuticals Inc | Method of treating cancer associated with a ras mutation |
| SG10202108194XA (en) | 2015-07-13 | 2021-09-29 | Beyondspring Pharmaceuticals Inc | Plinabulin compositions |
| RU2753543C1 (en) | 2016-02-08 | 2021-08-17 | Бейондспринг Фармасьютикалс, Инк. | Compositions containing tucaresol or analogues thereof |
| CN118304304A (en) | 2016-06-06 | 2024-07-09 | 大连万春布林医药有限公司 | Compositions and methods for reducing neutropenia |
| EP3565812B1 (en) | 2017-01-06 | 2023-12-27 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
| CN110381938A (en) | 2017-02-01 | 2019-10-25 | 大连万春布林医药有限公司 | The method for reducing neutrophil leucocyte deficiency disease |
| CN107569486A (en)* | 2017-08-23 | 2018-01-12 | 北京京佑奇康生物科技有限公司 | Menglusitena treats the new application of thrombopenia |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US11786523B2 (en) | 2018-01-24 | 2023-10-17 | Beyondspring Pharmaceuticals, Inc. | Composition and method for reducing thrombocytopenia |
| US11874276B2 (en) | 2018-04-05 | 2024-01-16 | Dana-Farber Cancer Institute, Inc. | STING levels as a biomarker for cancer immunotherapy |
| WO2022015794A1 (en) | 2020-07-14 | 2022-01-20 | Optimvia, Llc | Methods for synthesizing non-anticoagulant heparan sulfate |
| CA3127458A1 (en)* | 2019-01-25 | 2020-07-30 | Janssen Pharmaceutica Nv | Methods of enhancing protection against organ and vascular injury, hematopoietic recovery and survival in response to total body radiation/chemical exposure |
| CA3138100A1 (en) | 2019-04-17 | 2020-10-22 | Compass Pathfinder Limited | Treatment of depression and other various disorders with psilocybin |
| WO2021041532A1 (en)* | 2019-08-26 | 2021-03-04 | Dana-Farber Cancer Institute, Inc. | Use of heparin to promote type 1 interferon signaling |
| PH12022551169A1 (en)* | 2019-11-13 | 2024-02-19 | Astex Pharmaceuticals Inc | METHODS OF TREATING LSD1-RELATED DISEASES and Disorders WITH LSD1 INHIBITORS |
| WO2021207697A1 (en) | 2020-04-10 | 2021-10-14 | Cantex Pharmaceuticals, Inc. | Treatment of acute lung injury |
| US20240197723A1 (en) | 2021-04-09 | 2024-06-20 | Beyondspring Pharmaceuticals, Inc. | Therapeutic compositions and methods for treating tumors |
| KR102856472B1 (en) | 2021-10-21 | 2025-09-11 | 숙명여자대학교산학협력단 | Combination therapy with griseofulvin for blood cancer |
| CN116212020B (en)* | 2022-12-09 | 2025-05-30 | 中国医学科学院放射医学研究所 | Application of JAK inhibitor in medicine for preventing and treating radiation-induced bone marrow suppression and intestinal injury |
| CN116983325A (en)* | 2023-08-18 | 2023-11-03 | 首都儿科研究所 | Use of co-active ingredients for the preparation of a medicament for the treatment of tumors |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2374910A1 (en) | 1976-10-23 | 1978-07-21 | Choay Sa | PREPARATION BASED ON HEPARIN, INCLUDING LIPOSOMES, PROCESS FOR OBTAINING IT AND MEDICINAL PRODUCTS CONTAINING SUCH PREPARATIONS |
| US5804374A (en) | 1980-12-05 | 1998-09-08 | Massachusetts Insti. Technology | Nuclear factors associates with transcriptional regulation |
| FR2553287B1 (en) | 1983-10-18 | 1986-09-12 | Choay Sa | COMPOSITIONS BASED ON MUCOPOLYSACCHARIDES OR OLIGOSACCHARIDES, ESPECIALLY BASED ON HEPARIN FRACTIONS OR FRAGMENTS, SUITABLE FOR THE TREATMENT OF CELL PROLIFERATION DISORDERS |
| DE3422518A1 (en) | 1984-06-16 | 1985-12-19 | B. Braun Melsungen Ag, 3508 Melsungen | HEPARIN DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, MEDICINAL PRODUCTS CONTAINING THEM AND THEIR USE IN THE TREATMENT OF FATTY METABOLISM DISORDERS |
| FR2584606A1 (en) | 1985-07-12 | 1987-01-16 | Dropic | USE OF POLY- AND OLIGOSACCHARIDES FOR THE PRODUCTION OF ACTIVE MEDICAMENTS IN THE PATHOLOGIES OF CONNECTIVE TISSUE |
| US5380716A (en) | 1988-12-15 | 1995-01-10 | Glycomed, Inc. | Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation |
| IT1234826B (en) | 1989-01-30 | 1992-05-29 | Alfa Wassermann Spa | HEPARIN DERIVATIVES AND PROCEDURE FOR THEIR PREPARATION |
| US5399493A (en) | 1989-06-15 | 1995-03-21 | The Regents Of The University Of Michigan | Methods and compositions for the optimization of human hematopoietic progenitor cell cultures |
| WO1991015216A1 (en) | 1990-04-05 | 1991-10-17 | Kennedy Thomas P | Method and medicament for prevention or medication of human leucocyte elastase-mediated pulmonary diseases |
| US5250519A (en) | 1991-03-29 | 1993-10-05 | Glycomed Incorporated | Non-anticoagulant heparin derivatives |
| IT1254216B (en) | 1992-02-25 | 1995-09-14 | Opocrin Spa | POLYSACCHARIDIC DERIVATIVES OF HEPARIN, EPARAN SULPHATE, THEIR FRACTIONS AND FRAGMENTS, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| WO1993019734A1 (en) | 1992-04-02 | 1993-10-14 | Baker Norton Pharmaceuticals, Inc. | Method and composition for treating antigen-induced and exercise-induced asthma |
| US5668118A (en) | 1992-07-24 | 1997-09-16 | Cavalier Pharmaceuticals | Method of synthesis of 2-O-desulfated Heparin and use thereof for inhibition of elastase and Cathepspin G |
| US5306724A (en) | 1992-08-17 | 1994-04-26 | Clintec Nutrition Company | Method for preventing and treating atherosclerosis |
| GB2270841A (en) | 1992-09-09 | 1994-03-30 | Merck & Co Inc | Compositions for Treating vascular restenosis |
| US5696100A (en)* | 1992-12-22 | 1997-12-09 | Glycomed Incorporated | Method for controlling O-desulfation of heparin and compositions produced thereby |
| US5296471A (en) | 1992-12-22 | 1994-03-22 | Glycomed Incorporated | Method for controlling o-desulfation of heparin and compositions produced thereby |
| AU6246394A (en) | 1993-02-22 | 1994-09-14 | Cavalier Pharmaceuticals, Inc. | Use of heparin to inhibit interleukin-8 |
| SE9302135D0 (en) | 1993-06-18 | 1993-06-18 | Kabi Pharmacia Ab | NEW PHARMACEUTICAL COMPOSITION |
| US5994318A (en) | 1993-10-04 | 1999-11-30 | Albany Medical College | Cochleate delivery vehicles |
| US5840707A (en) | 1993-10-04 | 1998-11-24 | Albany Medical College | Stabilizing and delivery means of biological molecules |
| EP0758247A4 (en) | 1994-05-06 | 1997-08-20 | Glycomed Inc | O-desulfated heparin derivatives, methods of making and uses thereof |
| US5804560A (en) | 1995-01-06 | 1998-09-08 | Sibia Neurosciences, Inc. | Peptide and peptide analog protease inhibitors |
| JP4097044B2 (en) | 1996-07-29 | 2008-06-04 | パリンジェニックス，インコーポレイテッド | How to treat asthma with O-desulfated heparin |
| US6154502A (en) | 1996-08-22 | 2000-11-28 | Intel Corporation | Signal constellation slicer |
| US7258857B2 (en) | 1996-11-22 | 2007-08-21 | The Trustees Of Columbia University In The City Of New York | Rage-related methods for treating inflammation |
| NZ337364A (en) | 1997-02-15 | 2001-06-29 | Millennium Pharm Inc | Treatment of infarcts, ischemia and reperfusion through inhibition of NFkappaB |
| AU8657098A (en) | 1997-05-30 | 1998-12-30 | Arch Development Corporation | P-selectin translocation to vascular epithelial lumen by ionizing radiation |
| US6406862B1 (en) | 1998-10-06 | 2002-06-18 | The United States Of America As Represented By The Secretary Of The Army | Dip-stick assay for C-reactive protein |
| CN1326355A (en) | 1998-11-13 | 2001-12-12 | 伊莱利利公司 | Method of treating heparin-induced thrombocytopenia |
| US20030083231A1 (en)* | 1998-11-24 | 2003-05-01 | Ahlem Clarence N. | Blood cell deficiency treatment method |
| US6153217A (en) | 1999-01-22 | 2000-11-28 | Biodelivery Sciences, Inc. | Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents |
| US6514502B1 (en) | 1999-01-26 | 2003-02-04 | Schering-Plough Veterinary Corporation | Propagation of bovine cononavirus in chinese hamster ovary cells |
| EP1223948A2 (en) | 1999-09-13 | 2002-07-24 | CHARLOTTE-MECKLENBURG HOSPITAL doing business as Carolinas Medical Center | Method of inhibiting nf-kappa-b with heparin, for treating cardiovascular diseases and inflammations |
| US7781416B2 (en) | 2000-01-25 | 2010-08-24 | Sigma-Tau Research Switzerland S.A. | Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect |
| US6489311B1 (en) | 2000-05-02 | 2002-12-03 | Charlotte-Mecklenburg Hospital Authoirty | Method for the prevention of apoptosis |
| MXPA03009436A (en)* | 2001-04-18 | 2004-12-06 | Prometic Biosciences Inc | Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors. |
| US20040072796A1 (en) | 2002-04-18 | 2004-04-15 | Embury Stephen H. | Method and composition for preventing pain in sickle cell patients |
| EP1523310A2 (en) | 2002-07-09 | 2005-04-20 | The Scripps Research Institute | Method to inhibit ischemia and reperfusion injury |
| US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| AU2003293122A1 (en) | 2002-11-27 | 2004-06-23 | Massachusetts Institute Of Technology | Methods for synthesizing polysaccharides |
| US20040180812A1 (en)* | 2002-12-13 | 2004-09-16 | Technology Center | Methods of treating and preventing proliferative disease |
| WO2005000295A1 (en) | 2003-05-20 | 2005-01-06 | Transtech Pharma, Inc. | Rage antagonists as agents to reverse amyloidosis and diseases associated therewith |
| US7538096B2 (en) | 2004-03-16 | 2009-05-26 | The General Hospital Corporation | Treatment and prevention of abnormal cellular proliferation |
| EP1744764B1 (en)* | 2004-04-22 | 2012-05-30 | Celator Pharmaceuticals, Inc. | Liposomal formulations of anthracycline agents and cytidine analogs |
| US20050261241A1 (en) | 2004-05-19 | 2005-11-24 | Celsus Biopharmaceuticals, Inc. | Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses |
| US20050282775A1 (en) | 2004-06-16 | 2005-12-22 | Paringenix, Inc. | Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome |
| US7468358B2 (en) | 2004-06-16 | 2008-12-23 | Paringenix, Inc. | Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (HIT) syndrome |
| US20060040896A1 (en) | 2004-08-18 | 2006-02-23 | Paringenix, Inc. | Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity |
| JP2006076968A (en) | 2004-09-10 | 2006-03-23 | Seikagaku Kogyo Co Ltd | Physiologically active molecule-containing crosslinked heparin gel composition |
| CA2616166A1 (en) | 2005-07-22 | 2007-02-01 | The Regents Of The University Of California | Heparin compositions and selectin inhibition |
| WO2007019554A2 (en) | 2005-08-08 | 2007-02-15 | Momenta Pharmaceuticals, Inc. | Polysaccharides for delivery of active agents |
| CA2623735A1 (en) | 2005-09-30 | 2007-04-12 | Takara Bio Inc. | Method for production of t cell population |
| CN101336253A (en) | 2005-12-16 | 2008-12-31 | Dnp加拿大公司 | Chitin derivatives for hyperlipidemia |
| WO2007115372A1 (en) | 2006-04-10 | 2007-10-18 | Monash University | A method of modulating beta-amyloid peptide production |
| PL2043662T3 (en) | 2006-07-26 | 2016-03-31 | Intrexon Corp | Methods and compositions for treating disease |
| EP2061504A4 (en) | 2006-09-20 | 2010-01-27 | Univ Johns Hopkins | COMBINATORY THERAPY AGAINST CANCER AND INFECTIOUS DISEASES USING VACCINE AND ANTI-B7-H1 |
| WO2008106584A1 (en) | 2007-02-28 | 2008-09-04 | Paringenix, Inc. | O-desulfated heparins treating acute exacerbations of chronic obstructive pulmonary disease |
| AU2008260447B2 (en)* | 2007-06-01 | 2013-10-10 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
| JP2010534672A (en) | 2007-07-23 | 2010-11-11 | ユニバーシティ オブ ユタ リサーチ ファウンデーション | Method for blocking glycation end product receptor (RAGE) ligation |
| US8569262B2 (en) | 2007-11-02 | 2013-10-29 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
| WO2009117677A2 (en) | 2008-03-21 | 2009-09-24 | University Of Utah Research Foundation | Methods for controlling intracellular calcium levels associated with an ischemic event |
| BRPI0909849A2 (en) | 2008-04-04 | 2015-10-06 | Univ Utah Res Found | semi-synthetic glycosaminoglycosane ethers and methods for making and using them |
| US8476249B2 (en)* | 2009-05-07 | 2013-07-02 | Glaxosmithkline Llc | Method of treating thrombocytopenia |
| EP2482903B1 (en) | 2009-09-29 | 2018-11-14 | Vectura GmbH | Improved method for treatment of patients with cystic fibrosis |
| WO2011109877A1 (en) | 2010-03-12 | 2011-09-15 | The Australian National University | Heparan sulfate replacement therapy |
| WO2011116954A2 (en)* | 2010-03-24 | 2011-09-29 | Bioréalités S.A.S. | Prophylaxis of colorectal and gastrointestinal cancer |
| US10159705B2 (en) | 2010-06-28 | 2018-12-25 | Stemtech IP Holdings, LLC | Methods and compositions for enhancing stem cell mobilization |
| WO2012106299A1 (en)* | 2011-01-31 | 2012-08-09 | Celgene Corporation | Pharmaceutical compositions of cytidine analogs and methods of use thereof |
| WO2012106379A1 (en) | 2011-02-01 | 2012-08-09 | Paringenix, Inc. | Sensitization of cancer cells to treatment |
| WO2013016181A1 (en) | 2011-07-22 | 2013-01-31 | Paringenix, Inc. | Compositions and methods for anti-coagulation |
| CA2872104A1 (en) | 2012-05-01 | 2013-11-07 | Duke University | Compositions and methods for heparan sulfate as a biomarker for transplant rejection |
| CN108498532B (en) | 2012-05-09 | 2021-07-23 | 坎泰克斯制药股份有限公司 | Treatment of myelosuppression |
| WO2014134539A1 (en) | 2013-02-28 | 2014-09-04 | President And Fellows Of Harvard College | Methods and compositions for mobilizing stem cells |
| CN105848672A (en) | 2013-10-22 | 2016-08-10 | 坎泰克斯制药股份有限公司 | Methods of treating and preventing radiation damage |
| US20160296552A1 (en) | 2013-10-24 | 2016-10-13 | Cantex Pharmaceuticals, Inc. | Treating Bacterial Infections of the Lung |
| WO2015142924A1 (en) | 2014-03-17 | 2015-09-24 | Cantex Pharmaceuticals, Inc. | Multivalent cation formulations of partially desulfated heparins |
| EP3258941A4 (en) | 2015-02-17 | 2018-09-26 | Cantex Pharmaceuticals, Inc. | Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction |
| WO2016133907A1 (en) | 2015-02-17 | 2016-08-25 | Cantex Pharmaceuticals, Inc. | Adoptive cell transfer methods |
| US20170106011A1 (en) | 2015-10-20 | 2017-04-20 | Cantex Pharmaceuticals, Inc. | Methods of treating traumatic brain injury and sequelae |
| WO2017123549A1 (en) | 2016-01-11 | 2017-07-20 | Cantex Pharmaceuticals, Inc. | Methods of treating or preventing graft-versus-host disease using hmgb1-interacting heparinoids |
| Publication | Publication Date | Title |
|---|---|---|
| SG11201407340YA (en) | Treatment of myelosuppression | |
| SG11201906431UA (en) | Method for the treatment of thromboembolism | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201408405WA (en) | Engineered three-dimensional connective tissue constructs and methods of making the same | |
| SG11201810117WA (en) | Human platelet lysate derived extracellular vesicles for use in medicine | |
| SG11201909963YA (en) | Methods for treating dravet syndrome | |
| SG11201408261UA (en) | Syringe | |
| SG11201804117XA (en) | Neural cell extracellular vessicles | |
| SG11201805311XA (en) | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion | |
| SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
| SG11201407837WA (en) | Beta-hairpin peptidomimetics | |
| SG11201407512VA (en) | High-concentration monoclonal antibody formulations | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201408307VA (en) | Needle guard | |
| SG11201407200TA (en) | Liquid formulation | |
| SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
| SG11201408240TA (en) | Treatment of motor and movement disorder side effects associated with parkinson's disease treatments | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201408292YA (en) | Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same | |
| SG11201408509PA (en) | Racecadotril lipid compositions | |
| SG11201908052PA (en) | Lipid-based nanoparticles with enhanced stability | |
| SG11201806985WA (en) | Methods and reagents for prevention and/or treatment of infection | |
| SG11201407597XA (en) | Nucleophilic catalysts for oxime linkage | |
| SG11201810974QA (en) | Methods and compositions for prostate cancer diagnosis and treatment | |
| SG11201803816RA (en) | Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease |